Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/178663
Title: Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker
Author: Batlle López, Ana
González de Villambrosía, Sonia
Francisco, Mazorra
Malatxeberria, Sefora
Sáez, Anabel
Montalbán, Carlos
Sánchez, Lydia
García, Joan
González Barca, Eva
López-Hernández, Andrés
Ruiz-Marcellan, M. Carmen
Mollejo, Manuela
Grande, Cristina
Richards, Kristy L.
Hsi Eric D.
Tzankov, Alexandar
Visco, Carlo
Xu-Monette, Zijun Y.
Cao, Xin
Young, Ken H.
Piris, Miguel Ángel
Conde, Eulogio
Montes Moreno, Santiago
Keywords: Limfomes
Cèl·lules B
Immunoteràpia
Lymphomas
B cells
Immunotheraphy
Issue Date: 5-Apr-2016
Publisher: Impact Journals
Abstract: Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of aggressive lymphomas that can be classified into three molecular subtypes by gene expression profiling (GEP): GCB, ABC and unclassified. Immunohistochemistry-based cell of origin (COO) classification, as a surrogate for GEP, using three available immunohistochemical algorithms was evaluated in TMA-arranged tissue samples from 297 patients with de novo DLBCL treated by chemoimmunotherapy (R-CHOP and R-CHOP-like regimens). Additionally, the prognostic impacts of MYC, BCL2, IRF4 and BCL6 abnormalities detected by FISH, the relationship between the immunohistochemical COO classification and the immunohistochemical expression of MYC, BCL2 and pSTAT3 proteins and clinical data were evaluated. In our series, non-GCB DLBCL patients had significantly worse progression-free survival (PFS) and overall survival (OS), as calculated using the Choi, Visco-Young and Hans algorithms, indicating that any of these algorithms would be appropriate for identifying patients who require alternative therapies to R-CHOP. Whilst MYC abnormalities had no impact on clinical outcome in the non-GCB subtype, those patients with isolated MYC rearrangements and a GCB-DLBCL phenotype had worse PFS and therefore might benefit from novel treatment approaches.
Note: Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.7495
It is part of: Oncotarget, 2016, vol. 7, num. 14, p. 18036-18049
URI: http://hdl.handle.net/2445/178663
Related resource: https://doi.org/10.18632/oncotarget.7495
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
679871.pdf2.17 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons